Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.

Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.

RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL).Inhibition of endogenous pAKT by RV1001 in primary canine NHL cells was determined by Western blotting. A phase I study of RV1001...

Full description

Bibliographic Details
Main Authors: Heather L Gardner, Sarah B Rippy, Misty D Bear, Kim L Cronin, Heather Heeb, Holly Burr, Claire M Cannon, Kumar V Penmetsa, Srikant Viswanadha, Swaroop Vakkalanka, Cheryl A London
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5915681?pdf=render

Internet

http://europepmc.org/articles/PMC5915681?pdf=render

Similar Items